SanegeneBio has entered a $1.5bn global licensing agreement with Genentech, part of the Roche Group, for one of its ribonucleic acid interferences (RNAi) programmes utilising SanegeneBio’s technology platform. The deal grants Genentech exclusive global rights to develop and commercialise the selected RNAi programme. According to the contract, SanegeneBio will manage early development activities while Genentech will assume responsibility for all subsequent clinical development and global commercialisatio ...